NCT00412750View on ClinicalTrials.gov

Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

PHASE3TerminatedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Hepatitis B
Interventions
DRUG

Telbivudine (LdT)

600 mg orally once daily for 104 weeks.

DRUG

peginterferon alpha-2a

180 μg subcutaneous injection once a week for 52 weeks.

Trial Locations (1)

94115

Novartis, San Francisco

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00412750 - Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) | Biotech Hunter | Biotech Hunter